Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

NCT00144833 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

150

Enrollment

INDUSTRY

Sponsor class

Stopped Incomplete data

Conditions

HIV-1

Interventions

DRUG: fosamprenavir/ritonavir (700mg/100mg BID)
DRUG: fosamprenavir/ritonavir (1400mg/100mg BID)
DRUG: fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)

Sponsor

GlaxoSmithKline